EARLY DEVELOPMENT IN FRAGILE X SYNDROME: IMPLICATIONS FOR DEVELOPMENTAL SCREENING

被引:3
|
作者
Bailey, Donald B. [1 ]
Hazlett, Heather Cody [2 ]
Roberts, Jane E. [3 ]
Wheeler, Anne C. [2 ]
机构
[1] RTI Int, Social Stat & Environm Sci, Res Triangle Pk, NC USA
[2] Univ N Carolina, Carolina Inst Dev Disabil, Chapel Hill, NC USA
[3] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA
来源
INTERNATIONAL REVIEW OF RESEARCH IN DEVELOPMENTAL DISABILITIES: EARLY DEVELOPMENT IN NEUROGENETIC DISORDERS, VOL 40 | 2011年 / 40卷
关键词
FRONTAL-SUBCORTICAL CIRCUITS; MENTAL-RETARDATION PROTEIN; TISSUE-SPECIFIC EXPRESSION; FMR-1 FULL MUTATION; AUTISTIC BEHAVIOR; WHITE-MATTER; HEAD CIRCUMFERENCE; YOUNG-CHILDREN; MOUSE MODEL; HUMAN-BRAIN;
D O I
10.1016/B978-0-12-374478-4.00004-6
中图分类号
G76 [特殊教育];
学科分类号
040109 ;
摘要
Fragile X syndrome (FXS), the most common inherited form of intellectual disability, is not obvious at birth. The average age of diagnosis is around 36 months, a figure that has remained unchanged over the past decade. A primary challenge has been the lack of a definitive profile of early development in FXS. This chapter reviews the research that has been conducted relevant to this question. Research has been severely hampered by the fact that in the absence of population screening of newborns, it is virtually impossible to identify a sufficient and representative sample of infants to study. The research that has been conducted suggests that critical neurobiological processes are almost certainly affected in utero and in the early months of development. Consequently, many but not all males with FXS show delays during the latter part of the first year of life. This statement would be less true for females and for premutation carriers. We predict that a best case scenario for promoting earlier identification would be through regular developmental screening of infants in pediatric practice and rapid referral for genetic testing of any infant with developmental delays. Even if these policies could be implemented effectively, however, diagnosis of FXS would, at best, occur at an average age of 16-18 months. More research on early development is needed to further enhance understanding of clinical symptoms during the first year of life, but thus far it appears that a signature FXS profile will be difficult to identify. Population screening, such as newborn screening, will be the only realistic approach to identifying all children with FMR1 gene mutations.
引用
收藏
页码:75 / 108
页数:34
相关论文
共 50 条
  • [21] Auditory processing in fragile X syndrome
    Rotschafer, Sarah E.
    Razak, Khaleel A.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2014, 8
  • [22] Brief Report: Autistic Behaviors Among Children with Fragile X or Rett Syndrome: Implications for the Classification of Pervasive Developmental Disorder
    Michèle M. M. Mazzocco
    Margaret Pulsifer
    Agata Fiumara
    M. Cocuzza
    F. Nigro
    G. Incorpora
    R. Barone
    Journal of Autism and Developmental Disorders, 1998, 28 : 321 - 328
  • [23] Pathological Plasticity in Fragile X Syndrome
    Martin, Brandon S.
    Huntsman, Molly M.
    NEURAL PLASTICITY, 2012, 2012
  • [24] An "Omic" Overview of Fragile X Syndrome
    Dionne, Olivier
    Corbin, Francois
    BIOLOGY-BASEL, 2021, 10 (05):
  • [25] Molecular Biomarkers in Fragile X Syndrome
    Zafarullah, Marwa
    Tassone, Flora
    BRAIN SCIENCES, 2019, 9 (05)
  • [26] Translational endpoints in fragile X syndrome
    de Esch, Celine E. F.
    Zeidler, Shimriet
    Willemsen, Rob
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2014, 46 : 256 - 269
  • [27] Advances in the Treatment of Fragile X Syndrome
    Hagerman, Randi J.
    Berry-Kravis, Elizabeth
    Kaufmann, Walter E.
    Ono, Michele Y.
    Tartaglia, Nicole
    Lachiewicz, Ave
    Kronk, Rebecca
    Delahunty, Carol
    Hessl, David
    Visootsak, Jeannie
    Picker, Jonathan
    Gane, Louise
    Tranfaglia, Michael
    PEDIATRICS, 2009, 123 (01) : 378 - 390
  • [28] Targeted treatments in fragile X syndrome
    Hare, Emma B.
    Hagerman, Randi J.
    Lozano, Reymundo
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 531 - 543
  • [29] Modeling Fragile X Syndrome in Drosophila
    Drozd, Malgorzata
    Bardoni, Barbara
    Capovilla, Maria
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2018, 11
  • [30] Developmental expression of the neuroligins and neurexins in fragile X mice
    Lai, Jonathan K. Y.
    Doering, Laurie C.
    Foster, Jane A.
    JOURNAL OF COMPARATIVE NEUROLOGY, 2016, 524 (04) : 807 - 828